PolyPeptide Group AG (XSWX:PPGN) ROCE %: 1.15% (As of Dec. 2025)


XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
74 GF Score
Price CHF46.50
GF Value CHF30.72
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG ROCE %?

PolyPeptide Group AG XSWX:PPGN +4.38% 74 ROCE % is 1.15% as of Dec. 2025. GuruFocus rates XSWX:PPGN with a GF Score™ of 74/100 and a GF Value™ of CHF30.72 (Significantly Overvalued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PolyPeptide Group AG's annualized ROCE % for the quarter that ended in Dec. 2025 was 1.15%.

PolyPeptide Group AG  (XSWX:PPGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PolyPeptide Group AG ROCE % Related Terms

PolyPeptide Group AG ROCE % Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG ROCE % Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 16.16 1.94 -10.37 -1.70 -1.62

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.51 -1.50 -2.08 -4.66 1.15
XSWX:PPGN
74GF Score
PolyPeptide Group AG XSWX:PPGN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG ROCE % Calculation

PolyPeptide Group AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-9.077/( ( (706.349 - 181.59) + (770.734 - 174.061) )/ 2 )
=-9.077/( (524.759+596.673)/ 2 )
=-9.077/560.716
=-1.62 %

PolyPeptide Group AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=6.54/( ( (725.096 - 184.701) + (770.734 - 174.061) )/ 2 )
=6.54/( ( 540.395 + 596.673 )/ 2 )
=6.54/568.534
=1.15 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.15% mean?
PolyPeptide Group AG (XSWX:PPGN) has a ROCE % of 1.15% as of Dec. 2025.
Is PolyPeptide Group AG's ROCE % too high?
PolyPeptide Group AG's current ROCE % is 1.15%. The Drug Manufacturers industry median ROCE % is 7.00. PolyPeptide Group AG's value of 1.15% is 83.6% below this industry median. Overall, PolyPeptide Group AG has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's ROCE % compare to ZTS and UTHR?
PolyPeptide Group AG's ROCE % of 1.15% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. PolyPeptide Group AG's value of 1.15% is 83.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current ROCE % of 1.15% is 83.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current ROCE % is 1.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF30.72, compared to a current price of CHF46.50 — trading 51.4% above its estimated fair value. The current ROCE % is 1.15% and 83.6% below the Drug Manufacturers industry median of 7.00. PolyPeptide Group AG's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current ROCE % is 1.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF46.50 is trading 51.4% above its estimated GF Value™ of CHF30.72. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • ROCE %: 1.15%
  • GF Value™: CHF30.72 vs. price of CHF46.50 (51.4% above fair value)
  • GF Score™: 74/100 with 9 warning signs
  • Industry Position: 83.6% below the Drug Manufacturers median

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
74GF Score

Get the complete analysis for XSWX:PPGN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF46.50
Price
CHF30.72
GF Value